RxDoctor Payments Data

Colette Haywood, MD

Family Medicine · Lehigh Acres, FLNPI 1346545985

Payments from drug & device makers

$1,317in general payments, 2019–2025

Across 36 payments — averaging $36.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$314
  • Boehringer Ingelheim$267
  • Exact Sciences$178
  • Novo Nordisk$140
  • Lilly USA, LLC$131
  • AstraZeneca$130
  • plus $158 from 4 others

What the payments were for

  • Food & beverage$1,31099%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,317 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$22,802
Medicare patients
108
Services billed
639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin154$226,412
OzempicSemaglutide79$121,176
TrulicityDulaglutide43$106,481
MounjaroTirzepatide58$96,866
JanuviaSitagliptin Phosphate81$95,620
FarxigaDapagliflozin Propanediol60$84,375
GlyxambiEmpagliflozin/Linagliptin54$73,149
VascepaIcosapent Ethyl49$47,987
EliquisApixaban20$27,927
Diclofenac Sodium301$27,125
SynjardyEmpagliflozin/Metformin Hcl11$20,221
Bydureon BciseExenatide Microspheres13$17,917
Trijardy XrEmpaglifloz/Linaglip/Metformin20$14,708
MyrbetriqMirabegron14$14,455
XareltoRivaroxaban17$14,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Synjardy, Trijardy Xr$267$334,490239 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$131$206,404125 claims
Novo NordiskOzempic$140$121,17679 claims
AstraZenecaFarxiga, Symbicort$130$95,55696 claims
PfizerEliquis$40$27,92720 claims
Johnson & JohnsonXarelto$21$14,33717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Lehigh Acres

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →